间充质干细胞疗法在肾移植中的应用：一个未完待续的故事

谢思雨; 路君

doi:10.3969/j.issn.1674-7445.2023228

间充质干细胞疗法在肾移植中的应用：一个未完待续的故事

doi: 10.3969/j.issn.1674-7445.2023228

谢思雨,
路君^,

350025　福州，中国人民解放军联勤保障部队第九〇〇医院福建省移植生物学重点实验室

基金项目: 福建省自然科学基金面上项目（2023J01207）；中国人民解放军联勤保障部队第九〇〇医院重点学科支撑项目（2023XKYZ01）

详细信息

作者简介:

通讯作者:
路君（ORCID 0000-0003-2221-1872），Email：junlu.heather@xmu.edu.cn

中图分类号: R617,R329.2
计量
- 文章访问数: 174
- HTML全文浏览量: 62
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2023-11-02
- 网络出版日期: 2024-02-29
- 刊出日期: 2024-05-07

Application of mesenchymal stem cell therapy in kidney transplantation: a continued story

Xie Siyu,
Lu Jun^,

The 900th Hospital of the Joint Logistics Support Force of Chinese People's Liberation Army, Fujian Provincial Key Laboratory of Transplantation Biology, Fuzhou 350025, China

More Information

Corresponding author: Lu Jun, Email: junlu.heather@xmu.edu.cn

摘要

摘要: 免疫抑制药是预防器官移植术后排斥反应的主要手段，但会降低机体对病原体的反应能力，导致感染等的风险增加。近年来，间充质干细胞（MSC）疗法在实体器官移植领域的应用备受关注。临床前研究表明，MSC疗法能够延长移植肾存活时间，诱导免疫耐受，加速急性肾损伤修复，促进肾功能恢复。临床试验则验证了MSC疗法的安全性、耐受性和有效性。因此，本文对MSC的一般特性、MSC的免疫调节和组织修复作用以及MSC在肾移植临床试验中的应用进行综述，简要讨论待继续研究的问题和对未来的展望，旨在为推动MSC治疗在临床肾移植中的应用提供参考。
- 间充质干细胞 /
- 肾移植 /
- 免疫调节 /
- 组织修复 /
- 外泌体 /
- 免疫抑制药 /
- 排斥反应 /
- 炎症
Abstract: Immunosuppressant is one of the main preventive measures for rejection after organ transplantation, whereas it may reduce the host response capability to pathogens and increase the risk of infection. In recent years, the application of mesenchymal stem cell (MSC) therapy in the field of solid organ transplantation has attracted widespread attention. Preclinical studies have shown that MSC therapy may prolong the survival time of transplant kidney, induce immune tolerance, accelerate the repair of acute kidney injury and promote the recovery of renal function. Clinical trials have confirmed the safety, tolerance and effectiveness of MSC therapy. Consequently, general characteristics, immunomodulation and tissue repair function of MSC, and the application of MSC in clinical trials of kidney transplantation were reviewed, the unresolved issues were briefly discussed and the prospects for subsequent research were predicted, aiming to provide reference for promoting the application of MSC therapy in clinical kidney transplantation.
- Mesenchymal stem cell /
- Kidney transplantation /
- Immunomodulation /
- Tissue repair /
- Exosome /
- Immunosuppressant /
- Rejection /
- Inflammation

HTML全文

下载: 全尺寸图片幻灯片

参考文献(58)

[1]	GUO Z, LUO T, MO R, et al. Ischemia-free organ transplantation - a review[J]. Curr Opin Organ Transplant, 2022, 27(4): 300-304. DOI: 10.1097/MOT.0000000000000998.
[2]	MASSICOTTE-AZARNIOUCH D, DETWILER RK, HU Y, et al. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis[J]. Nephrol Dial Transplant, 2023, 38(9): 2009-2018. DOI: 10.1093/ndt/gfac337.
[3]	YOHANNAN B, SRIDHAR A, KAUR H, et al. Screening for renal cell carcinoma in renal transplant recipients: a single-centre retrospective study[J]. BMJ Open, 2023, 13(9): e071658. DOI: 10.1136/bmjopen-2023-071658.
[4]	邱煜程, 周显玉, 刘菲, 等. 间充质干细胞及其外泌体在移植中的应用进展[J]. 组织工程与重建外科杂志, 2023, 19(2): 184-188. DOI: 10.3969/j.issn.1673-0364.2023.02.016. QIU YC, ZHOU XY, LIU F, et al. Application progress of mesenchymal stem cells and their exosomes in allotransplantation[J]. J Tissue Eng Reconstr Surg, 2023, 19(2): 184-188. DOI: 10.3969/j.issn.1673-0364.2023.02.016.
[5]	冯星, 靳洪涛, 马隽, 等. 间充质干细胞治疗炎性关节炎的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(2): 87-92. DOI: 10.3877/cma.j.issn.2095-1221.2023.02.004. FENG X, JI HT, MA J, et al. Progress in the treatment of inflammatory arthritis with mesenchymal stem cells[J/OL]. Chin J Cell Stem Cell (Electr Edit), 2023, 13(2): 87-92. DOI: 10.3877/cma.j.issn.2095-1221.2023.02.004.
[6]	MARGIANA R, MARKOV A, ZEKIY AO, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review[J]. Stem Cell Res Ther, 2022, 13(1): 366. DOI: 10.1186/s13287-022-03054-0.
[7]	ZANG L, LI Y, HAO H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial[J]. Stem Cell Res Ther, 2022, 13(1): 180. DOI: 10.1186/s13287-022-02848-6.
[8]	SINGH J, SINGH S. Review on kidney diseases: types, treatment and potential of stem cell therapy[J]. Ren Replace Ther, 2023, 9(1): 21. DOI: 10.1186/s41100-023-00475-2.
[9]	高世春, 冯一梅, 高蕾, 等. 维多珠单抗治疗糖皮质激素耐药急性肠道移植物抗宿主病2例报告并文献复习[J]. 中华血液学杂志, 2022, 43(12): 1046-1049. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.013. GAO SC, FENG YM, GAO L, et al. Vedolizumab for treatment of steroid-refractory intestinal acute graft-versus-host disease: two cases report and literature review[J]. Chin J Hematol, 2022, 43(12): 1046-1049. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.013.
[10]	DOMINICI M, LE BLANC K, MUELLER I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4): 315-317. DOI: 10.1080/14653240600855905.
[11]	HUANG Y, WU Q, TAM PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications[J]. Int J Mol Sci, 2022, 23(17): 10023. DOI: 10.3390/ijms231710023.
[12]	SEL FA, OGUZ FS. Regenerative medicine application of mesenchymal stem cells[J]. Adv Exp Med Biol, 2022, 1387: 25-42. DOI: 10.1007/5584_2022_713.
[13]	ZARIPOVA LN, MIDGLEY A, CHRISTMAS SE, et al. Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases[J]. Int J Mol Sci, 2023, 24(22): 16040. DOI: 10.3390/ijms242216040.
[14]	PISTOIA V, RAFFAGHELLO L. Mesenchymal stromal cells and autoimmunity[J]. Int Immunol, 2017, 29(2): 49-58. DOI: 10.1093/intimm/dxx008.
[15]	DEO D, MARCHIONI M, RAO P. Mesenchymal stem/stromal cells in organ transplantation[J]. Pharmaceutics, 2022, 14(4): 791. DOI: 10.3390/pharmaceutics14040791.
[16]	DE MARTINO M, ZONTA S, RAMPINO T, et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation[J]. Transplant Proc, 2010, 42(4): 1331-1335. DOI: 10.1016/j.transproceed. 2010.03.079.
[17]	洪政, 王峰. 间充质干细胞在同种异体心脏移植中诱导免疫耐受的进展[J]. 湖北民族大学学报(医学版), 2022, 39(4): 56-59. HONG Z, WANG F. Progress of mesenchymal stem cells inducing immune tolerance in allogeneic heart transplantation[J]. J Hubei Univ (Med Edit), 2022, 39(4): 56-59.
[18]	GARCIA SG, SANDOVAL-HELLÍN N, CLOS-SANSALVADOR M, et al. Mesenchymal stromal cells induced regulatory B cells are enriched in extracellular matrix genes and IL-10 independent modulators[J]. Front Immunol, 2022, 13: 957797. DOI: 10.3389/fimmu.2022.957797.
[19]	FOUZA A, TAGKOUTA A, DAOUDAKI M, et al. Exploring perturbations in peripheral B cell memory subpopulations early after kidney transplantation using unsupervised machine learning[J]. J Clin Med, 2023, 12(19): 6331. DOI: 10.3390/jcm12196331.
[20]	UNAR A, BERTOLINO L, PATAUNER F, et al. Decoding sepsis-induced disseminated intravascular coagulation: a comprehensive review of existing and emerging therapies[J]. J Clin Med, 2023, 12(19): 6128. DOI: 10.3390/jcm12196128.
[21]	YANG S, ZHAO M, JIA S. Macrophage: key player in the pathogenesis of autoimmune diseases[J]. Front Immunol, 2023, 14: 1080310. DOI: 10.3389/fimmu.2023.1080310.
[22]	GAO S, MAO F, ZHANG B, et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways[J]. Exp Biol Med (Maywood), 2014, 239(3): 366-375. DOI: 10.1177/1535370213518169.
[23]	SCHRODT MV, BEHAN-BUSH RM, LISZEWSKI JN, et al. Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes[J]. Stem Cell Res Ther, 2023, 14(1): 206. DOI: 10.1186/s13287-023-03443-z.
[24]	蔡海军. 间充质干细胞在组织修复和再生中应用的研究进展[J]. 重庆医学, 2023, 52(5): 782-786. DOI: 10.3969/j.issn.1671-8348.2023.05.030. CAI HJ. Advances in the application of mesenchymal stem cells in tissue repair and regeneration[J]. Chongqing Med, 2023, 52(5): 782-786. DOI: 10.3969/j.issn.1671-8348.2023.05.030.
[25]	YANG J, XIAO M, MA K, et al. Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: atopic dermatitis and psoriasis[J]. Front Immunol, 2023, 14: 1092668. DOI: 10.3389/fimmu.2023.1092668.
[26]	BLONDEEL J, GILBO N, DE BONDT S, et al. Stem cell derived extracellular vesicles to alleviate ischemia-reperfusion injury of transplantable organs. a systematic review[J]. Stem Cell Rev Rep, 2023, 19(7): 2225-2250. DOI: 10.1007/s12015-023-10573-7.
[27]	PODESTÀ MA, REMUZZI G, CASIRAGHI F. Mesenchymal stromal cell therapy in solid organ transplantation[J]. Front Immunol, 2021, 11: 618243. DOI: 10.3389/fimmu.2020.618243.
[28]	FRANQUESA M, HERRERO E, TORRAS J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model[J]. Stem Cells Dev, 2012, 21(17): 3125-3135. DOI: 10.1089/scd.2012.0096.
[29]	马元, 庄雪莹, 陈旭. 间充质干细胞外泌体调控血管生成机制的研究进展[J]. 中国医科大学学报, 2021, 50(10): 944-947. DOI: 10.12007/j.issn.0258-4646.2021.10.016. MA Y, ZHUANG XY, CHEN X. Advances in research regarding the mechanisms whereby mesenchymal stem cell-derived exosomes regulate angiogenesis[J]. J China Med Univ, 2021, 50(10): 944-947. DOI: 10.12007/j.issn.0258-4646.2021.10.016.
[30]	LEE K, JANG HR. Role of T cells in ischemic acute kidney injury and repair[J]. Korean J Intern Med, 2022, 37(3): 534-550. DOI: 10.3904/kjim.2021.526.
[31]	RAMA I, GRINYÓ JM. Malignancy after renal transplantation: the role of immunosuppression[J]. Nat Rev Nephrol, 2010, 6(9): 511-519. DOI: 10.1038/nrneph.2010.102.
[32]	PERICO N, CASIRAGHI F, TODESCHINI M, et al. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy[J]. Front Immunol, 2018, 9: 1359. DOI: 10.3389/fimmu.2018.01359.
[33]	TAN J, WU W, XU X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial[J]. JAMA, 2012, 307(11): 1169-1177. DOI: 10.1001/jama.2012.316.
[34]	MUDRABETTU C, KUMAR V, RAKHA A, et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study[J]. Nephrology (Carlton), 2015, 20(1): 25-33. DOI: 10.1111/nep.12338.
[35]	REINDERS ME, DE FIJTER JW, ROELOFS H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study[J]. Stem Cells Transl Med, 2013, 2(2): 107-111. DOI: 10.5966/sctm.2012-0114.
[36]	PENG Y, KE M, XU L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study[J]. Transplantation, 2013, 95(1): 161-168. DOI: 10.1097/TP.0b013e3182754c53.
[37]	PAN GH, CHEN Z, XU L, et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study[J]. Oncotarget, 2016, 7(11): 12089-12101. DOI: 10.18632/oncotarget.7725.
[38]	LEE H, PARK JB, LEE S, et al. Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study[J]. J Transl Med, 2013, 11: 96. DOI: 10.1186/1479-5876-11-96.
[39]	SUN Q, HUANG Z, HAN F, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial[J]. J Transl Med, 2018, 16(1): 52. DOI: 10.1186/s12967-018-1422-x.
[40]	ERPICUM P, WEEKERS L, DETRY O, et al. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study[J]. Kidney Int, 2019, 95(3): 693-707. DOI: 10.1016/j.kint.2018.08.046.
[41]	DREYER GJ, GROENEWEG KE, HEIDT S, et al. Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: the Neptune study, a phase I single-center study[J]. Am J Transplant, 2020, 20(10): 2905-2915. DOI: 10.1111/ajt.15910.
[42]	WU X, WANG Z, WANG J, et al. Exosomes secreted by mesenchymal stem cells induce immune tolerance to mouse kidney transplantation via transporting lncRNA DANCR[J]. Inflammation, 2022, 45(1): 460-475. DOI: 10.1007/s10753-021-01561-5.
[43]	曾可君, 杨煜辉, 胡喆. 外泌体在重要脏器缺血再灌注损伤中的治疗作用研究进展[J]. 中国医药导报, 2022, 19(25): 33-37. DOI: 10.20047/j.issn1673-7210.2022.25.07. ZENG KJ, YANG YH, HU Z. Research progress on the therapeutical effect of exosomes in ischemia reperfusion injury in important organs[J]. China Med Herald, 2022, 19(25): 33-37. DOI: 10.20047/j.issn1673-7210.2022.25.07.
[44]	CAO Q, HUANG C, CHEN XM, et al. Mesenchymal stem cell-derived exosomes: toward cell-free therapeutic strategies in chronic kidney disease[J]. Front Med (Lausanne), 2022, 9: 816656. DOI: 10.3389/fmed.2022.816656.
[45]	KERN S, EICHLER H, STOEVE J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue[J]. Stem Cells, 2006, 24(5): 1294-1301. DOI: 10.1634/stemcells.2005-0342.
[46]	ABBASI B, SHAMSASENJAN K, AHMADI M, et al. Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications[J]. Stem Cell Res Ther, 2022, 13(1): 97. DOI: 10.1186/s13287-022-02777-4.
[47]	CROP MJ, BAAN CC, KOREVAAR SS, et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients[J]. Transplantation, 2009, 87(6): 896-906. DOI: 10.1097/TP.0b013e31819b3d72.
[48]	NAUTA AJ, WESTERHUIS G, KRUISSELBRINK AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting[J]. Blood, 2006, 108(6): 2114-2120. DOI: 10.1182/blood-2005-11-011650.
[49]	BURON F, PERRIN H, MALCUS C, et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells[J]. Transplant Proc, 2009, 41(8): 3347-3352. DOI: 10.1016/j.transproceed.2009.08.030.
[50]	POPP FC, EGGENHOFER E, RENNER P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate[J]. Transpl Immunol, 2008, 20(1/2): 55-60. DOI: 10.1016/j.trim.2008.08.004.
[51]	GE W, JIANG J, BAROJA ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance[J]. Am J Transplant, 2009, 9(8): 1760-1772. DOI: 10.1111/j.1600-6143.2009.02721.x.
[52]	KAUNDAL U, BAGAI U, RAKHA A. Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation[J]. J Transl Med, 2018, 16(1): 31. DOI: 10.1186/s12967-018-1403-0.
[53]	PERICO N, CASIRAGHI F, INTRONA M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility[J]. Clin J Am Soc Nephrol, 2011, 6(2): 412-422. DOI: 10.2215/CJN.04950610.
[54]	CASIRAGHI F, AZZOLLINI N, TODESCHINI M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation[J]. Am J Transplant, 2012, 12(9): 2373-2383. DOI: 10.1111/j.1600-6143.2012.04115.x.
[55]	WU B, SHI X, JIANG M, et al. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment[J]. Mol Cancer, 2023, 22(1): 38. DOI: 10.1186/s12943-023-01748-4.
[56]	GNIADEK TJ, GARRITSEN HSP, STRONCEK D, et al. Optimal storage conditions for apheresis research (OSCAR): a biomedical excellence for safer transfusion (BEST) Collaborative study[J]. Transfusion, 2018, 58(2): 461-469. DOI: 10.1111/trf.14429.
[57]	DRELA K, STANASZEK L, NOWAKOWSKI A, et al. Experimental strategies of mesenchymal stem cell propagation: adverse events and potential risk of functional changes[J]. Stem Cells Int, 2019: 7012692. DOI: 10.1155/2019/7012692.
[58]	LECHANTEUR C, BRIQUET A, BETTONVILLE V, et al. MSC manufacturing for academic clinical trials: from a clinical-grade to a full GMP-compliant process[J]. Cells, 2021, 10(6): 1320. DOI: 10.3390/cells10061320.